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Clinical benefit of gluten-free diet in screen-
detected older celiac disease patients
Anitta Vilppula1, Katri Kaukinen2,3, Liisa Luostarinen1, Ilkka Krekelä4, Heikki Patrikainen4, Raisa Valve5,
Markku Luostarinen6, Kaija Laurila7, Markku Mäki3,7 and Pekka Collin2,3*
Abstract
Background: The utility of serologic screening for celiac disease is still debatable. Evidence suggests that the
disorder remains undetected even in the older population. It remains obscure whether screening makes good or
harm in subjects with long-standing gluten ingestion. We evaluated whether older subjects benefit from active
detection and subsequent gluten free dietary treatment of celiac disease.
Methods: Thirty-five biopsy-proven patients aged over 50 years had been detected by serologic mass screening.
We examined the disease history, dietary compliance, symptoms, quality of life and bone mineral density at
baseline and 1-2 years after the commencement of a gluten-free diet. Symptoms were evaluated by
gastrointestinal symptom rating scale and quality of life by psychological general well-being questionnaires. Small
bowel biopsy, serology, laboratory parameters assessing malabsorption, and bone mineral density were
investigated.
Results: Dietary compliance was good. The patients had initially low mean serum ferritin values indicating
subclinical iron deficiency, which was restored by a gluten-free diet. Vitamin B12, vitamin D and erythrocyte folic
acid levels increased significantly on diet. Celiac patients had a history of low-energy fractures more often than the
background population, and the diet had a beneficial effect on bone mineral density. Alleviation in gastrointestinal
symptoms was observed, even though the patients reported no or only subtle symptoms at diagnosis. Quality of
life remained unchanged. Of all the cases, two thirds would have been diagnosed even without screening if the
family history, fractures or concomitant autoimmune diseases had been taken carefully into account.
Conclusions: Screen-detected patients benefited from a gluten-free diet. We encourage a high index of suspicion
and active case-finding in celiac disease as an alternative to mass screening in older patients.
Background
Evidence suggests that the incidence of celiac disease
increases with age [1,2]. Physicians’ lack of alertness in
the older people may result in a significant delay in
diagnosis, as celiac disease is widely deemed to be a
condition affecting younger subjects. Indeed, the major-
ity of older celiac disease patients have remained unde-
tected, often due to the absence of symptoms [3,4]. It is
reasonable to assume that, due to long gluten exposure,
older patients with untreated celiac disease may be dis-
posed to severe nutritional deficiencies, even when they
are seemingly asymptomatic. In particular, the rate of
bone loss is accelerated in women after the menopause,
likewise in men at the same age. We know that even
young and asymptomatic patients with celiac disease
may have reduced bone mineral density while untreated
[5], and the condition might be even more evident in
older [6].
On the other hand, a lifelong gluten-free diet is
restrictive and may also increase the burden of illness
and impairs quality of life [7,8]. Especially in the older
subjects the diet may not be well tolerated, as patients
will have adopted lifetime dietary habits which may be
hard to break. Moreover, if a gluten-free diet does not
necessarily produce any clinical improvement, screen-
detected cases may not be motivated to adhere strictly
to it. Therefore, to clarify the benefit of serologic screen-
ing for celiac disease in older population, a follow-up of
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the previously undiagnosed patients identified by screen-
ing is required [6].
In this prospective study we evaluated the benefits of
active serologic population-based mass screening for
celiac disease and subsequent dietary treatment in sub-
jects over 50 years of age. The aim was to establish
whether celiac disease should be rigorously searched for
in the older people.
Methods
Patients and study design
We identified screen-detected new celiac disease
patients enrolled from a cohort representing the older
Finnish population. The original study population com-
prised 4272 randomly selected individuals born in the
years 1946-50, 1936-40 and 1926-30, and was defined
for a 10-year research project on ageing and well-being
(Good Ageing in the Lahti region = GOAL) http://www.
palmenia.helsinki.fi/ikihyva/InEnglish.html. In 2002, alto-
gether 2815 subjects (66%) consented to participate and
serum samples were drawn and stored at -20°C until
used. Anti-tissue transglutaminase antibodies were
tested from the stored sera in 2004, and 48 new seropo-
sitive cases were identified; their diagnostic work-up has
been published elsewhere [2]. Four had started a gluten-
free diet before enrolment, 39 of the remainder con-
sented to a small bowel biopsy, and villous atrophy with
crypt hyperplasia compatible with celiac disease was
found in 35. These 35 comprised the current study
group; their median age was 61 years (range 52-76) and
57% were female.
At baseline the patients were interviewed for their
family history, associated disorders and symptoms of
celiac disease. Nutritional condition and quality of life
were evaluated. The patients were advised to start a glu-
ten-free diet, and dietary counseling was carried out by
a gastroenterologist and a dietician. To ensure dietary
response and adherence to a gluten-free diet, an inter-
view by the dietitian, small bowel biopsies and celiac
disease antibodies were investigated after a median of
one year; nutritional condition and quality of life were
assessed after a median of two years on a gluten-free
diet. The diet was considered strict when there were no
signs of dietary transgressions upon the interview. Occa-
sional gluten-free diet was defined as a gluten intake
occurring less often than once in the month.
Small bowel mucosal biopsy
Small bowel mucosal biopsy samples were taken by upper
gastrointestinal endoscopy from the distal part of the duo-
denum. Three samples were paraffin-embedded, pro-
cessed, stained with hematoxylin-eosin and studied under
light microscopy. The villous height/crypt depth ratio (Vh/
CrD) was calculated from well orientated biopsy
specimens as previously described [9]; a ratio < 2 was con-
sidered abnormal and indicative of active celiac disease.
The densities of intraepithelial lymphocytes (IELs) were
counted from randomly selected surface epithelium and
expressed as IELs per 100 epithelial cells [9].
Celiac serology and HLA
IgA-class tissue transglutaminase antibodies (TGA) were
investigated by enzyme-linked immunosorbent assay
(Celikey; Phadia, Freiburg, Germany) according to man-
ufacturer’s instructions; values ≥5.0 arbitrary units (U)
were considered elevated. TGA-positive sera were
further analyzed for IgA-class endomysial antibodies
(EMA) by an indirect immunofluorescence method
using human umbilical cord as substrate; a dilution of
1:5 or more was considered positive [10].
The study patients were genotyped for HLA-DQB1*02,
DQB1*0302 and DQA1*05 alleles using the DELFIA
Coeliac Disease Hybridization Assay (Perkin-Elmer Life
and Analytic Sciences, Wallac Oy, Turku, Finland)
according to manufacturer’s instructions; DQB1*02 and
DQA1*05 corresponding to associated alleles for HLA
DQ2 and DQB1*0302 for HLA DQ8.
Clinical symptoms
The clinical symptoms were classified into three differ-
ent subgroups: (i) no symptoms, (ii) subtle symptoms
with occasionally one or more of the following: abdom-
inal pain, flatulence, belching, loose stools, tiredness,
joint pain or oral blisters, and (iii) classical symptoms
with constant abdominal complaints, diarrhea or exces-
sive weight loss. Abdominal complaints were addition-
ally evaluated by the Gastrointestinal Symptom Rating
Scale (GSRS), which denotes the total score derived
from five different gastrointestinal symptoms; diarrhea,
indigestion, constipation, abdominal pain and gastro-
esophageal reflux; a higher score indicates more severe
symptoms [11]. Quality of life was appraised by the Psy-
chological General Well Being (PGWB) questionnaire
[12]. This is a 22-item questionnaire including both
negative and positive affective states divided into six
parts: anxiety, depressed mood, positive well-being, self-
control, health and vitality; here a higher score denotes
better quality of life. Both questionnaires have been
widely employed in celiac disease. A total of 110 sub-
jects served as non-celiac controls for GSRS and PGWB.
The controls for GSRS and PGWB were collected form
the general population. We asked celiac members of the
Finnish celiac society to recruit an individual living in
their neighbourhood and not suffering from celiac dis-
ease. They had similar age and sex distribution as the
study subjects. Celiac disease was not systematically
excluded in controls, but the subjects reported no symp-
toms and had no relatives with celiac disease.
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Assessment of nutritional condition
Body mass index was computed as weight/height2 (kg/
m2). Blood hemoglobin, erythrocyte folic acid levels,
serum iron, ferritin, ionized calcium, phosphate and
vitamin A, B-12, D-25 and E concentrations were mea-
sured using routine laboratory methods.
Bone mineral density and history of fractures
Bone mineral density was measured by dual-energy X-
ray absorptiometry (GE Medical Systems, LUNAR, UK)
in the spine (L1 to L4) and right femoral neck. Values
were expressed as standard deviation (SD) scores, which
compare individual values to the mean bone mineral
density of sex-matched young adults (T score) or of the
age- and sex-matched population (Z score). T scores
above -1.0 SD represented normal values, scores
between -1.0 and -2.4 osteopenia and scores ≤ -2.5 SD
osteoporosis. When indicated, bisphosphonate medica-
tion together with supplementary calcium and vitamin
D were recommended, since it was considered unethical
to postpone medical treatment and wait for the effect of
a gluten-free diet.
The number of low-energy bone fractures was
extracted from the questionnaires of the original GOAL
study, equally in the total (n = 2815) series and in study
subjects.
Ethical considerations
The study was accepted by the Ethical Committee of
Päijät-Häme Central Hospital, and written informed
consent was obtained from all participants. Research is
in compliance with the Helsinki Declaration.
Statistics
Data were given as means with 95% confidence intervals
(CI) or medians with lower and upper quartiles and
range when appropriate. Chi-square or Fisher’s tests
were used in cross tabulations Wilcoxon signed or
paired rank test to compare changes within the study
group. A p value < 0.05 was considered statistically sig-
nificant. We calculated that, for the statistical power of
0.80 at a significance level of 0.05, 30 subjects would be
sufficient. We estimated that the difference of > 0.5 in
the Vh/CrD and that of 0.5 in GSRS were clinically sig-
nificant [13,14].
Results
Baseline findings
All 35 new celiac disease patients identified by mass
screening consented to participate (Table 1). Celiac dis-
ease-related genetic susceptibility markers were found in
all. Ten (29%) out of 35 had a family history of celiac
disease and 10 (29%) one or several autoimmune dis-
eases. Table 1 displays subjects in whom clinical features
would make case-finding by active screening possible.
Fourteen were reported to suffer from subtle, one from
classical symptoms, and 20 had no symptoms prior to
the diagnosis of celiac disease. Blood hemoglobin levels
were below reference values in four (13%), serum iron
in two (6%), ferritin in nine (26%), vitamin B12 in six
(17%), erythrocyte folic acid in 13 (37%), serum phos-
phate in three (9%) and vitamin E levels in one (3%).
Iron or folic acid supplement were given when consid-
ered ethically justified. Osteopenia was found in 14 and
osteoporosis in eight (altogether in 62%). Eight (23%)
out of 35 had a history of low-energy fractures; for com-
parison, in the whole GOAL study, low-energy fractures
were reported in 123 (4%) out of 2815 o subjects, the
difference being statistically significant (p < 0.01). None
of the new celiac disease patients was under-weight. At
baseline, GSRS and PGWB scores did not differ from
those in the control series (Table 2), although the GSRS
scores were in general higher in celiac patients, indicat-
ing more gastrointestinal symptoms.
Gluten-free dietary treatment
Thirty-two (91%) of the 35 screen-detected older celiac
disease patients consented to start a gluten-free diet.
Twenty-seven maintained a strict diet, and five had
occasional transgressions less often than once in the
month; three patients did not commence gluten-free
diet.
After one year on the diet, small bowel mucosal vil-
lous morphology improved and densities of IELs
decreased statistically significantly in the 26 who agreed
to undergo the follow-up biopsy (Figure 1). In parallel,
serum TGA levels normalized.
Clinical symptoms resolved in 14 out of the 15 who
reported symptoms at the time of diagnosis. One with
initially subtle abdominal complaints developed diarrhea
despite small bowel mucosal normalization on a strict
gluten-free diet; colonoscopy showed no abnormal find-
ings or inflammation. In accordance with the clinical
history, alleviation in gastrointestinal symptoms was
observed both by GSRS total score and by subscores,
and was statistically significant, except in the case of
constipation (Table 2).
Mean serum ferritin and vitamin B12, D and E values
improved significantly in those 32 who started the glu-
ten-free diet (Table 3). By contrast, mean serum vitamin
A and ionized calcium values decreased after com-
mencement of diet, albeit remaining within normal
reference range. There was also a small albeit statisti-
cally significant decrease in blood hemoglobin levels in
females. To verify that the beneficial effects were due to
gluten-free diet, we analyzed separately patients who did
not receive any additional medical iron or vitamin sub-
stitution. The beneficial effect remained significant in
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serum iron (12 excluded, p = 0.042), serum ferritin (12,
p > 0.001), vitamin B12 (14, p = 0.039), and vitamin D
(21, p = 0.006).
The mean femoral Z-score improved significantly
when patients had adhered to the gluten-free diet for
two years; in the lumbar spine the improvement did not
reach statistical significance (Table 4). There were no
significant changes in T-scores. In subjects with osteo-
penia or osteoporosis, the mean T-score increased in
lumbar spine from -2.0 (95%CI -2.3 to -1.7) to -1.7 (95%
CI -2.1 to-1.3), and in femoral neck from -2.2 (95%CI
-2.5 to -1.9) to -2.1 (95%CI -2.4 to -1.8) (p-values 0.03
and 0.20, respectively). Bisphosphonates were prescribed
for three patients with osteoporosis or osteopenia.
When these patients were excluded from the analysis,
the increase in lumbar spine T-score remained still sta-
tistically significant (p = 0.021). The diet had no obvious
effect on BMI. Quality of life measured by PGWB did
not change during the follow-up; apart from improve-
ment in the well-being score (Table 2). The three
patients who declined the diet initially reported no
symptoms, but developed minor abdominal complaints
Table 1 Clinical features
Case Gender
Age (y)
tTGAa EMAb Symptoms Mal-absorption Diagnostic clues for detecting celiac disease
1 M 52 > 100 1:2000 Subtle Vitamin B12 deficiency
2 M 52 29.2 1:2000 None - Fracture of hand
3 F 52 > 100 1:4000 None + Pernicious anemia, hypothyroidism
4 F 52 8.2 1:50 None + Blisters in mouth, family history
5 F 52 35.7 1:500 Subtle -
6 F 52 > 100 1:2000 Subtle +
7 M 53 29.7 1:200 Subtle - Sarcoidosis, family history
8 M 53 6.1 1:5 Subtle - Family history
9 F 53 6.2 0 Subtle + Fracture of vertebra, osteomalacia hypothyroidism
10 M 54 88.3 1:1000 None + Fracture of ankle, psoriasis
11 M 54 93.0 1:500 None +
12 F 55 > 100 1:500 Subtle - Sjögren’s syndrome, psoriasis
13 F 55 43.4 1:500 None - Osteoporosis
14 M 55 24.5 1:200 Subtle + Psoriasis, osteoporosis
15 F 56 58.5 1:200 Classic - Family history
16 F 56 18.3 1:50 None - Family history
17 F 56 46.6 1:1000 None - Type I diabetes mellitus, hypothyroidism
18 M 62 97.4 1:500 None + Depression, vitamin B12 deficiency
19 F 63 5.8 1:5 None +
20 M 63 38.9 1:1000 Subtle + Sarcoidosis, osteoporosis
21 F 63 94.1 1:200 None - Hypothyroidism
22 F 63 16.5 1:100 None + Hyperthyroidism, family history
23 F 64 71.2 1:500 None + Fracture of ribs and sternum, osteoporosis
24 M 64 5.8 1:5 None + Fracture of wrist
25 F 64 10.5 1:5 None -
26 F 65 > 100 1:500 Subtle + Osteoporosis
27 F 65 64.3 1:200 Subtle - Hypothyroidism, family history
28 F 66 79.8 1:500 Subtle + Hypothyroidism, family history
29 M 72 > 100 1:200 Subtle + Fracture of foot, family history
30 M 73 27.4 1:50 Subtle +
31 M 73 20.2 1:200 None + Fracture of ribs, osteoporosis blisters in mouth
32 M 75 6.0 1:5 None + Osteoporosis
33 F 76 7.4 1:5 None - Osteoporosis
34 M 76 5.4 1:5 None + Fracture of ribs, family history
35 F 76 48.3 1:500 None - Stomach cancer
Clinical features of screen-detected celiac disease patients having small bowel mucosal villous atrophy at the time of diagnosis.
A Serum IgA-class tissue transglutaminase antibodies, values > 5.0 U/l abnormal
B Serum IgA-class endomysial antibodies, titers 1:≥5 abnormal
C Sarcoidosis treated with immunosuppressive medication
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Table 2 Symptoms and quality of life
Screen-detected celiac patients
At the diagnosis After gluten-free diet p-valuea Non-celiac controls p-value b
GSRS c
Diarrhea 2.1 (1.7-2.6) 1.5 (1.2-1.9) 0.009 1.6 (1.5-1.8) 0.091
Indigestion 2.8 (2.4-3.2) 2.0 (1.6-2.3) < 0.001 2.4 (2.0-2.7) 0.117
Constipation 2.1 (1.7-2.5) 1.8 (1.5-2.1) 0.343 2.0 (1.6-2.3) 0.813
Abdominal pain 2.1 (1.7-2.4) 1.7 (1.4-2.0) 0.020 1.8 (1.5-2.1) 0.203
Reflux 1.8 (1.4-2.2) 1.4 (1.2-1.7) 0.040 1.5 (1.8-1.2) 0.161
Total score 2.2 (1.9-2.5) 1.7 (1.5-2.0) 0.001 1.9 (1.7-2.1) 0.133
PGWBd
Anxiety 23 (21-24) 24 (22-25) 0.256 25 (24-26) 0.063
Depression 16 (15-17) 16 (15-17) 0.429 16 (16-17) 0.713
Well-being 16 (15-17) 17 (16-18) 0.011 17 (16-17) 0.364
Self-control 15 (14-16) 15 (14-16) 0.942 15 (15-16) 0.593
General health 13 (12-14) 12 (11-14) 0.243 14 (14-15) 0.030
Vitality 17 (16-18) 18 (16-19) 0.100 19 (18-19) 0.110
Total score 100 (93-106) 102 (95-109) 0.620 106 (104-108) 0.355
Gastrointestinal symptom score (GSRS) and psychological general well-being (PGWB) in older celiac disease patients before and after dietary treatment,
compared to non-celiac controls
a Comparison between celiac patients at the diagnosis and after gluten-free diet
b Comparison between celiac patients at the diagnosis and non-celiac controls
c Gastrointestinal symptom rating scale; higher scores indicate more gastro-intestinal symptoms
d Psychological general well-being; higher scores indicate better quality of life
Figure 1 Small bowel mucosa before and after gluten-free diet. The villous height crypt depth ratio (A) and the densities of intraepithelial
lymphocytes/100 enterocytes (B) at the time of diagnosis and after one year on a gluten free diet (GFD) in older celiac disease patients
detected by mass-screening.
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after the follow-up; in two osteopenia and low folic acid
levels remained.
Discussion
An increasing number of patients with celiac disease will
be diagnosed among the older people [1-3]. The correct
diagnosis may have been missed even when the patients
had contacted their physicians for many years due to
unexplained symptoms or abnormalities in blood tests
[3]. Altogether, older patients may have more symptoms
than younger ones [15], and may have an increased risk
of malabsorption or enteropathy-associated T-cell lym-
phoma[16]. Anemia, iron, vitamin B12, folic acid, and
calcium deficiency have been the major malnutrition
findings in older celiac disease patients [3,16]. It would
thus, appear desirable to detect the disease as early as
possible.
On the other hand, it is of crucial importance to know
what the overall implications of the diagnosis are in
older people. Mortality has not increased among older
undiagnosed celiac disease patients [6] and the effect of
the diagnosis on well-being has not been investigated. In
this prospective follow-up study we evaluated the conse-
quences of dietary treatment in a definite celiac disease
patient series obtained by population-based mass
screening in the older [17]. Since neither celiac disease
nor any abdominal disease was the target of the original
GOAL project, there was no selection bias towards indi-
viduals suffering from gastrointestinal symptoms. Of
note, the rate of detection of celiac disease in Finland is
relatively high, and in the present series, 0.9% of indivi-
duals already had the diagnosis of celiac disease estab-
lished before the screening program [17]. This
notwithstanding, even here the majority of older celiac
disease patients would have remained undiagnosed with-
out active screening or case finding.
In these screen-detected patients an improvement in
GSRS was evident under dietary treatment, both in total
score and in virtually in all subscores, displaying an alle-
viation in gastrointestinal symptoms. The effect of the
treatment on quality of life (PGWB) was not so evident,
but it is of note that the diet did not worsen it. A com-
parable finding was obtained in our recent study where
celiac patients detected by screening at risk groups were
investigated [18]. An improvement in laboratory values
was seen almost invariably. This was most evident in
serum mean ferritin indicating the presence of subclini-
cal iron deficiency, as the serum iron levels remained
Table 3 Malabsorption
Reference values At the diagnosis After gluten-free diet p-value
Mean Range Mean Range
Blood hemoglobin M: 13.4-16.7 g/dl 14.1 11.6-16.4 14.3 11.9-16.0 0.225
F: 11.7-15.5 g/dl 13.8 12.0-15.6 13.3 10.7-16.1 0.019
Serum iron 10-34 μmol/l 17 5-28 19 9-40 0.280
Serum ferritin M: 20-275 μg/l 46 5-177 120 7-351 0.004
F: 7-205 μg/l 33 5-78 83 7-351 0.001
Serum vitamin B12 150-740 pmol/l 275 110-542 355 142-739 0.018
Erythrocyte folic acid 180-845 nmol/l 290 88-662 403 108-1292 0.058
Serum vitamin D25 22-103 nmol/l 45 15-77 64 29-97 < 0.001
Plasma phosphorus 0.71-1.53 mmol/l 0.94 0.59-1.19 0.93 0.72-1.24 0.382
Serum vitamin A 1.0-3.0 μmol/l 2.2 1.1-3.3 2.0 1.0-2.5 0.025
Serum vitamin E 12-48 μmol/l 30 10-42 35 25-65 0.005
Serum ionized calcium 1.15-1.30 mmol/l 1.23 1.15-1.33 1.22 1.15-1.32 0.049
Malabsorption parameters at the diagnosis and after gluten-free diet in 32 screen-detected older celiac disease patients. Some of the patients received also
vitamin or iron supplements, see the text.
Table 4 Bone density and body mass index
At the diagnosis After gluten-free diet
Mean; 95% confidence intervals Mean; 95% confidence intervals
Lumbar spine Z-score (SD) 0.6 0.0 - 1.1 0.9 0.1 - 1.5 0.060
Femoral Z-score (SD) -0.1 -0.5 - 0.2 0.1 -0.2 - 0.6 0.009
Lumbar spine T-score (SD) -0.7 -1.2 - -0.1 -0.4 -1.2 - 0.1 0.241
Femoral T-score (SD) -1.1 -1.5 - -0.6 -1.1 -1.5 - -0.5 0.670
Body mass index (kg/m2) 25.9 24.6-27.1 25.3 24.1-26.5 0.139
Bone mass density (T and Z -score) and body mass index (mean with 95% confidence intervals (CI)) at diagnosis and after gluten-free diet in 32 screen-detected
older celiac disease patients
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within normal range. A low ferritin level was similarly
observed in a series from Godfrey and colleagues [6].
Apart from gluten-free diet, iron or vitamin supplemen-
tation was given to some of our patients, but the benefi-
cial effect was evident also in those subjects, who did
not receive any substitution. There was a slight but sta-
tistically significant decrease in blood hemoglobin levels
in females (Table 3), but none of the patients suffered
from severe anemia. A regular follow-up of hemoglobin
values is in any case indicated in celiac patients.
A risk of low bone mineral density is possible in
screen-detected apparently asymptomatic celiac disease
patients [5]. In the present study, Z-scores, reflecting
the values in the age- and sex-matched population, were
within reference levels at baseline, but a significant
improvement was observed on a gluten-free diet. As Z-
score reference values usually decrease with age, we
concluded that this process was slowed down by dietary
treatment. Though no improvement was observed in T-
scores in the total series, such an effect was seen in sub-
jects with osteoporosis or osteopenia, even when sub-
jects treated with bisphosphonates were excluded. The
analysis would have been impossible if also subjects
receiving vitamin D or calcium substitution were
excluded. On the other hand, in the randomized study
carried out by Mautalen et al. [19], strict gluten-free
diet promoted a significant increase in bone mineral
density, but calcium and vitamin D supplementation did
not provide additional benefit. We will further point
out, that the medical management for bone disease of
malabsorption would not have been possible without
our active screening. There was a small but significant
decrease in serum calcium levels. This may be due to
ongoing bone restoration, which implies that calcium
substitution is indicated after the commencement of a
gluten-free diet. Our results further suggest that low-
energy fractures may be a risk in untreated celiac dis-
ease. Larger prospective studies are however needed to
confirm this finding.
Compliance with a gluten-free diet does not seem to
be a problem in older patients with celiac disease, as
compliance rates have been more than 90% [3]. Accord-
ingly, the histological or serological recovery in the 32
patients adhering to a gluten-free was virtually complete.
However, our results cannot directly be applied in every
country, as the availability of gluten-fee diet may not be
as good as in Finland. Another limitation of the study
was that we did not have laboratory or bone mineral
density values for the control group. Nevertheless, we
emphasize that a favorable outcome can be achieved by
screening older population for celiac disease.
None of our celiac disease patients suffered from
severe malabsorption syndrome, and they did not have
refractory sprue or any other severe complications.
Ten (29%) of these 35 screen-detected celiac patients
had had relatives with celiac disease and 10 autoim-
mune diseases, which should both alert to celiac dis-
ease. Katz and associates [20] concluded that
symptoms do not predict who will have celiac disease,
making case-finding ineffective, and they therefore sug-
gested that general population screening may be
needed to find the disorder. To the contrary, we
believe that in this older population case finding will
be effective as long as symptoms and risk-groups are
taken into account. Altogether, 29 out of 35 of our
celiac patients would have been detected without sero-
logic mass-screening if family history, bone fractures
or concomitant diseases (Table 1) had alerted the phy-
sicians (in patient 35 routine duodenal biopsy would
have detected celiac disease). We therefore recommend
screening in groups, where the costs are lower than in
mass-screening, and as shown here, the patients bene-
fit from dietary treatment.
Conclusions
Screen-detected, apparently asymptomatic older celiac
disease patients may suffer from subclinical malabsorp-
tion, gastrointestinal symptoms or bone disease, which
are alleviated during gluten-free dietary treatment. No
deterioration in quality of life was seen in our series,
and dietary compliance was excellent. Despite this, we
consider that there is still insufficient evidence to advo-
cate mass screening, until the costs and benefits of the
approach have been thoroughly evaluated. Instead, as
the majority of patients had a family history or asso-
ciated conditions known to occur with celiac disease, we
recommend active case finding in older people belong-
ing to at-risk groups.
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